Exelixis Past Earnings Performance
Past criteria checks 4/6
Exelixis's earnings have been declining at an average annual rate of -30.8%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 17% per year. Exelixis's return on equity is 9.2%, and it has net margins of 11.4%.
Key information
-30.8%
Earnings growth rate
-32.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 17.0% |
| Return on equity | 9.2% |
| Net Margin | 11.4% |
| Next Earnings Update | 30 Apr 2024 |
Recent past performance updates
Recent updates
Exelixis, Inc.'s (NASDAQ:EXEL) Earnings Haven't Escaped The Attention Of Investors
Apr 22
Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024
Mar 28We Ran A Stock Scan For Earnings Growth And Exelixis (NASDAQ:EXEL) Passed With Ease
Feb 26Exelixis: Bullish Despite The High Stakes Game Of Cabometyx Patent Battles
Jan 17Exelixis, Inc.'s (NASDAQ:EXEL) Revenues Are Not Doing Enough For Some Investors
Dec 27An Intrinsic Calculation For Exelixis, Inc. (NASDAQ:EXEL) Suggests It's 49% Undervalued
May 30Exelixis initiated at outperform at JMP Securities on cash flow, Cabometyx franchise
Oct 18Exelixis: Efforts Continue To Diversify The Pipeline
Sep 15Exelixis, Teva fight over Cabometyx generic again
Sep 06Exelixis Needs To Move Away From Its Overdependence On Cabozantinib
Aug 03Exelixis again sues MSN Pharmaceuticals over Cabometyx generic
Jul 19Exelixis to pay Ryvu $3M upfront in license deal to develop targeted cancer drugs
Jul 07Exelixis: Becoming A Giant Pharma
May 18Exelixis: Beyond The Cabozantinib Franchise
Apr 21Revenue & Expenses BreakdownBeta
How Exelixis makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1,830 | 208 | 543 | 1,044 |
| 30 Sep 23 | 1,774 | 92 | 531 | 1,136 |
| 30 Jun 23 | 1,714 | 164 | 507 | 1,002 |
| 31 Mar 23 | 1,664 | 154 | 488 | 969 |
| 31 Dec 22 | 1,611 | 182 | 460 | 892 |
| 30 Sep 22 | 1,638 | 308 | 440 | 777 |
| 30 Jun 22 | 1,555 | 273 | 426 | 742 |
| 31 Mar 22 | 1,521 | 298 | 402 | 691 |
| 31 Dec 21 | 1,435 | 231 | 402 | 694 |
| 30 Sep 21 | 1,254 | 164 | 385 | 626 |
| 30 Jun 21 | 1,157 | 94 | 371 | 639 |
| 31 Mar 21 | 1,031 | 65 | 333 | 605 |
| 31 Dec 20 | 988 | 112 | 293 | 548 |
| 30 Sep 20 | 958 | 152 | 269 | 488 |
| 30 Jun 20 | 998 | 282 | 232 | 409 |
| 31 Mar 20 | 979 | 294 | 231 | 376 |
| 31 Dec 19 | 968 | 321 | 228 | 337 |
| 30 Sep 19 | 956 | 612 | 223 | 300 |
| 30 Jun 19 | 910 | 642 | 219 | 247 |
| 31 Mar 19 | 856 | 650 | 212 | 208 |
| 31 Dec 18 | 854 | 690 | 206 | 182 |
| 30 Sep 18 | 745 | 368 | 200 | 157 |
| 30 Jun 18 | 672 | 323 | 190 | 141 |
| 31 Mar 18 | 585 | 253 | 179 | 127 |
| 31 Dec 17 | 452 | 154 | 159 | 112 |
| 30 Sep 17 | 410 | 150 | 126 | 104 |
| 30 Jun 17 | 320 | 58 | 120 | 95 |
| 31 Mar 17 | 257 | 6 | 116 | 90 |
| 31 Dec 16 | 191 | -70 | 116 | 96 |
| 30 Sep 16 | 124 | -147 | 120 | 96 |
| 30 Jun 16 | 71 | -181 | 106 | 101 |
| 31 Mar 16 | 43 | -186 | 83 | 103 |
| 31 Dec 15 | 37 | -162 | 57 | 96 |
| 30 Sep 15 | 35 | -178 | 50 | 113 |
| 30 Jun 15 | 31 | -195 | 42 | 130 |
| 31 Mar 15 | 30 | -229 | 46 | 157 |
| 31 Dec 14 | 25 | -261 | 51 | 189 |
| 30 Sep 14 | 22 | -281 | 55 | 199 |
| 30 Jun 14 | 21 | -286 | 58 | 203 |
| 31 Mar 14 | 27 | -275 | 55 | 201 |
| 31 Dec 13 | 31 | -245 | 51 | 179 |
| 30 Sep 13 | 35 | -226 | 47 | 162 |
| 30 Jun 13 | 43 | -192 | 41 | 145 |
Quality Earnings: EXEL has high quality earnings.
Growing Profit Margin: EXEL's current net profit margins (11.4%) are higher than last year (11.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EXEL's earnings have declined by 30.8% per year over the past 5 years.
Accelerating Growth: EXEL's earnings growth over the past year (14%) exceeds its 5-year average (-30.8% per year).
Earnings vs Industry: EXEL earnings growth over the past year (14%) exceeded the Biotechs industry -8.9%.
Return on Equity
High ROE: EXEL's Return on Equity (9.2%) is considered low.